Non-sterile liquid manufacturing demands more than filling capacity. It requires a CDMO that can manage formulation complexity, scale-up risk, microbiological control, packaging compatibility, and regulatory expectations without losing sight of day-to-day operational realities. At Adragos Leipzig, we support non-sterile liquid products through a practical, quality-led manufacturing model designed to take programmes from development through to commercial supply. Adragos positions Leipzig as a specialist site for semi-solids and non-sterile liquids, while its wider network adds formulation, analytical and regulatory support around that core manufacturing capability.
Why non-sterile liquid manufacturing requires the right CDMO
For pharmaceutical companies, non-sterile liquids can be highly effective dosage forms, but they also bring specific manufacturing challenges. Product performance depends not only on the formulation itself, but also on consistent mixing, controlled filling, suitable packaging, validated analytical methods, and robust microbial controls. These factors become more important as a programme moves from laboratory or pilot work into routine GMP manufacture. Regulatory frameworks also place clear expectations on finished pharmaceutical manufacturing, quality systems, and process control.
That is why partner selection matters. A capable CDMO for non-sterile liquids should be able to connect development knowledge with manufacturing execution, so that the intent of the formulation is maintained during transfer, scale-up, and commercial production. Adragos presents this integrated model through its development services, commercial manufacturing platform, and Leipzig manufacturing site.
Capabilities for oral solutions, suspensions and other non-sterile liquids
Adragos identifies non-sterile liquids as a core commercial manufacturing area and highlights oral solutions among the dosage forms supported within that platform. The Leipzig site is specifically described as specialising in semi-solid and non-sterile liquid pharmaceuticals, making it a logical manufacturing base for programmes that need focused liquid dosage expertise.
Oral solutions
Oral solutions require consistent solubility, uniformity, filling accuracy, and packaging compatibility. For many products, success also depends on taste-masking, dosing convenience, and reliable performance across the intended shelf life. Adragos’ non-sterile liquids capability page highlights oral solutions as part of its offering, with bottle options and support for varied formulation requirements.
Suspensions and other complex liquid systems
Suspensions and similar liquid systems add further complexity because physical stability, redispersibility, particle control, and homogeneity become critical to product performance. These products often require particularly careful alignment between formulation work, process design, in-process controls, and packaging configuration. Adragos also lists suspensions within its non-sterile liquids platform, supporting the positioning of Leipzig as a site for more demanding liquid dosage-form programmes as well as straightforward solutions.
From development to commercial manufacture
A strong non-sterile liquid manufacturing programme depends on continuity across development and manufacture. The aim is not simply to produce a batch, but to establish a process that remains robust as volumes increase, specifications tighten, and regulatory documentation expands. Adragos describes a broader drug development offering that includes formulation and analytical work, alongside a commercial manufacturing network intended to support later-stage supply.
Formulation and analytical development
Formulation development is where manufacturability begins. Adragos’ formulation development service references preformulation, formulation optimisation, process development, and technology transfer, with explicit reference to Quality by Design and scale-up considerations. Its analytical development service covers method development and validation, forced degradation, finished product controls, transfer of analytical methods, and ICH stability-related work. Together, those capabilities are relevant to non-sterile liquid products where formulation behaviour, preservative strategy, release methods, and stability performance all need to be understood before routine manufacture.
Scale-up, transfer and commercial readiness
As programmes move towards launch, scale-up and transfer need disciplined execution. Parameters that appear manageable at small scale can behave differently in larger vessels, on different filling lines, or with different packaging components. Adragos’ development pages explicitly reference scale-up and technology transfer, and its commercial manufacturing pages position the network for manufacturing and packaging of liquid products under GMP conditions. That is the operating bridge buyers usually need when selecting a CDMO for non-sterile liquid manufacturing.
Quality control and microbiological risk management
Quality control is central to non-sterile pharmaceutical manufacturing because the dosage form can be particularly sensitive to contamination, variability, and shelf-life drift. In non-sterile liquids, manufacturers must maintain microbiological quality within defined limits and apply controls across raw materials, process environment, equipment, and packaging. European GMP guidance, US CGMP regulations, and pharmacopoeial microbiological quality expectations all reinforce that principle.
Microbiological control in non-sterile liquids
Non-sterile does not mean uncontrolled. Microbiological control remains a core requirement, especially for water-containing formulations and products intended for patient populations that may be more vulnerable. The European Pharmacopoeia discussion material for chapter 5.1.4 addresses microbiological quality expectations for non-sterile pharmaceutical preparations, while GMP frameworks require manufacturing systems that consistently protect product quality. In practice, that means designing the process and facility around prevention, monitoring, and disciplined response rather than relying on end-product testing alone.
Stability and release testing
For liquid products, stability data is not a formality. It underpins shelf life, storage conditions, packaging decisions, and long-term product reliability. ICH Q1A(R2) defines the stability data package expected for new drug substances and products, and Adragos’ own service pages highlight both analytical development and drug stability testing within its platform. For non-sterile liquid programmes, that combination is especially relevant because stability can be affected by formulation chemistry, preservative performance, packaging interaction, and environmental conditions.
Facility, equipment and packaging capabilities in Leipzig
Manufacturing performance depends heavily on the practical fit between product, equipment, and site setup. Adragos describes Leipzig as a pharmaceutical manufacturing site in Germany specialising in semi-solids and non-sterile liquids, and it has also announced investment in a new cGMP-compliant liquid filling line and cartoning machine at the site. That matters because non-sterile liquid programmes often depend on efficient, repeatable filling and packaging operations as much as they depend on formulation know-how.
Packaging is equally important. Container choice, closure integrity, dosing aid compatibility, line configuration, and market-specific presentation all influence product quality and supply execution. Adragos maintains a dedicated pharmaceutical packaging service and presents packaging as part of its commercial manufacturing model. For non-sterile liquid manufacturing, that integrated approach can help reduce handover gaps between bulk manufacture and finished packed product.
Regulatory support for non-sterile liquid products
Regulatory readiness should be built into the programme from the outset rather than added at the end. Manufacturing data, analytical methods, stability studies, quality documentation, and process controls all need to support the product’s registration and lifecycle management strategy. Adragos presents regulatory services alongside its development and manufacturing capabilities, which is relevant for companies that need support across more than one phase of the product journey.
For non-sterile liquid products, this is particularly important where packaging configurations, market requirements, microbiological expectations, or product-specific control strategies add complexity. A manufacturing partner should therefore be able to align operational execution with regulatory documentation, not treat them as separate workstreams. That is consistent with the integrated service model described across Adragos’ site.
Why teams choose Adragos Leipzig for non-sterile liquids
Adragos Leipzig combines site-level specialisation in non-sterile liquids with access to wider development, analytical, packaging, and regulatory services across the Adragos network. For outsourcing teams, that matters because the challenge is rarely just to find manufacturing capacity. The real requirement is to secure a partner that can maintain product quality, manage operational risk, and support commercial readiness as the programme evolves. Adragos’ published service structure and Leipzig site positioning support that proposition.
For companies evaluating a CDMO for non-sterile liquid manufacturing, the most important questions are practical. Can the partner support development and transfer sensibly. Can it control microbiological and process risk. Can it align manufacturing, packaging, testing, and documentation. Can it scale with the programme. Leipzig is positioned to answer those questions through a specialist non-sterile liquid manufacturing base supported by broader Adragos capabilities.
FAQs about Non-sterile Liquids
What are non-sterile liquids in pharmaceutical manufacturing?
Non-sterile liquids are liquid pharmaceutical products that are not required to be sterile, but still need to meet strict quality, safety, and microbiological standards. They commonly include oral solutions, suspensions, syrups, drops, and certain topical liquid formulations.
What is non-sterile liquid manufacturing?
Non-sterile liquid manufacturing is the development, processing, filling, packaging, and quality control of liquid pharmaceutical products that do not require sterile processing. It involves careful control of formulation behaviour, mixing, filling accuracy, packaging compatibility, and microbiological quality.
Which products are typically classified as non-sterile liquids?
Typical non-sterile liquid dosage forms include oral solutions, oral suspensions, syrups, drops, mouthwashes, and some topical liquids. The exact classification depends on the route of administration, formulation design, and regulatory requirements for the product.
Why is microbiological control important in non-sterile liquids?
Microbiological control is critical because non-sterile does not mean uncontrolled. Many liquid formulations, especially water-based products, can support microbial growth if the formulation, equipment, environment, or packaging are not properly managed. Control measures usually include preservative strategy, validated cleaning, environmental controls, and routine testing.
What are the main challenges in non-sterile liquid manufacturing?
The main challenges include maintaining formulation uniformity, controlling viscosity, preventing contamination, achieving accurate fill volumes, selecting suitable packaging, and ensuring product stability over shelf life. These challenges often become more significant during scale-up and commercial transfer.
What is the difference between oral solutions and suspensions?
Oral solutions contain active ingredients fully dissolved in the liquid phase, which can simplify dose uniformity. Suspensions contain dispersed particles, so they require tighter control of particle behaviour, redispersibility, homogeneity, and physical stability throughout manufacturing and shelf life.
How does scale-up affect non-sterile liquid products?
Scale-up can change how a formulation behaves during mixing, holding, transfer, and filling. Parameters that work well at laboratory scale may not perform in the same way in larger vessels or on commercial lines. That is why process development and technology transfer are important for non-sterile liquid manufacturing.
What should companies look for in a CDMO for non-sterile liquids?
Companies should look for a CDMO with relevant dosage form experience, suitable development and analytical support, strong microbiological and quality systems, appropriate filling and packaging capabilities, and a proven approach to scale-up and commercial supply. The right partner should be able to connect formulation intent with reliable GMP execution.
Why is packaging important for non-sterile liquid products?
Packaging plays a direct role in product protection, usability, dosing accuracy, and shelf-life performance. Bottle material, closure system, dosing aid, and compatibility with the formulation all need to be considered carefully during development and commercial manufacture.
What testing is typically required for non-sterile liquids?
Testing may include assay, identity, impurities, pH, viscosity, microbial limits, preservative effectiveness where relevant, fill volume, appearance, and stability studies. The exact package depends on the product type, formulation risks, regulatory requirements, and intended market.
How important is stability testing for non-sterile liquids?
Stability testing is essential because it demonstrates how the product performs over time under defined storage conditions. For non-sterile liquids, it helps confirm shelf life, packaging suitability, preservative performance, and overall product quality throughout the lifecycle.
